Aarey Drugs & Pharmaceuticals Limited (BOM:524412)
India
· Delayed Price · Currency is INR 69.20
-1.28 (-1.82%)
At close: Mar 9, 2026
BOM:524412 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 3,909 | 4,739 | 3,956 | 4,190 | 4,928 | 3,484 | Upgrade
|
| Other Revenue | - | - | 69.65 | - | 1.73 | 30.12 | Upgrade
|
| Revenue | 3,909 | 4,739 | 4,026 | 4,190 | 4,929 | 3,514 | Upgrade
|
| Revenue Growth (YoY) | -32.97% | 17.73% | -3.91% | -15.01% | 40.27% | 16.79% | Upgrade
|
| Cost of Revenue | 3,843 | 4,621 | 3,819 | 4,039 | 4,721 | 3,378 | Upgrade
|
| Gross Profit | 65.46 | 118.23 | 206.4 | 150.87 | 208.51 | 136.38 | Upgrade
|
| Selling, General & Admin | 8.46 | 16.74 | 14.21 | 15.54 | 20.46 | 3.96 | Upgrade
|
| Other Operating Expenses | 29.14 | 30.9 | 77.5 | 52.67 | 67.9 | 40.91 | Upgrade
|
| Operating Expenses | 61.74 | 67.09 | 108.69 | 83.95 | 108.24 | 54.07 | Upgrade
|
| Operating Income | 3.73 | 51.15 | 97.71 | 66.92 | 100.27 | 82.31 | Upgrade
|
| Interest Expense | -33.95 | -35.42 | -41.95 | -25.4 | -18.13 | -23.18 | Upgrade
|
| Interest & Investment Income | 56.04 | 56.04 | - | 26.33 | 20.09 | 24.29 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.48 | 0.48 | -0.52 | -4.49 | 0.39 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 31.3 | -11.23 | -1.8 | -3.26 | -2.24 | -0.44 | Upgrade
|
| Pretax Income | 57.59 | 61.02 | 53.43 | 60.1 | 100.37 | 83.01 | Upgrade
|
| Income Tax Expense | 23.24 | 20.78 | 6.59 | 22.39 | 34.82 | 17.87 | Upgrade
|
| Net Income | 34.35 | 40.24 | 46.84 | 37.71 | 65.55 | 65.14 | Upgrade
|
| Net Income to Common | 34.35 | 40.24 | 46.84 | 37.71 | 65.55 | 65.14 | Upgrade
|
| Net Income Growth | -39.80% | -14.09% | 24.20% | -42.47% | 0.62% | 12.44% | Upgrade
|
| Shares Outstanding (Basic) | 29 | 28 | 25 | 25 | 24 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 28 | 25 | 25 | 24 | 23 | Upgrade
|
| Shares Change (YoY) | 4.15% | 11.18% | -0.26% | 5.84% | 2.95% | - | Upgrade
|
| EPS (Basic) | 1.20 | 1.42 | 1.84 | 1.48 | 2.72 | 2.79 | Upgrade
|
| EPS (Diluted) | 1.19 | 1.42 | 1.84 | 1.48 | 2.72 | 2.79 | Upgrade
|
| EPS Growth | -42.64% | -22.83% | 24.32% | -45.59% | -2.36% | 12.44% | Upgrade
|
| Free Cash Flow | - | 50.96 | -37.16 | -23.25 | -17.03 | 25.98 | Upgrade
|
| Free Cash Flow Per Share | - | 1.80 | -1.46 | -0.91 | -0.71 | 1.11 | Upgrade
|
| Gross Margin | 1.68% | 2.50% | 5.13% | 3.60% | 4.23% | 3.88% | Upgrade
|
| Operating Margin | 0.10% | 1.08% | 2.43% | 1.60% | 2.03% | 2.34% | Upgrade
|
| Profit Margin | 0.88% | 0.85% | 1.16% | 0.90% | 1.33% | 1.85% | Upgrade
|
| Free Cash Flow Margin | - | 1.07% | -0.92% | -0.56% | -0.34% | 0.74% | Upgrade
|
| EBITDA | 25.03 | 70.6 | 114.69 | 82.66 | 120.15 | 91.51 | Upgrade
|
| EBITDA Margin | 0.64% | 1.49% | 2.85% | 1.97% | 2.44% | 2.60% | Upgrade
|
| D&A For EBITDA | 21.3 | 19.45 | 16.98 | 15.74 | 19.88 | 9.2 | Upgrade
|
| EBIT | 3.73 | 51.15 | 97.71 | 66.92 | 100.27 | 82.31 | Upgrade
|
| EBIT Margin | 0.10% | 1.08% | 2.43% | 1.60% | 2.03% | 2.34% | Upgrade
|
| Effective Tax Rate | 40.36% | 34.05% | 12.34% | 37.25% | 34.69% | 21.53% | Upgrade
|
| Revenue as Reported | 4,050 | 4,838 | 4,026 | 4,217 | 4,954 | 3,554 | Upgrade
|
| Advertising Expenses | - | 3.36 | 1.71 | 2.56 | 3.89 | 1.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.